Patents
Literature
Patsnap Eureka AI that helps you search prior art, draft patents, and assess FTO risks, powered by patent and scientific literature data.

7 results about "Ebola virus" patented technology

Ebola virus is one of five known viruses within the genus Ebolavirus. Four of the five known ebolaviruses, including EBOV, cause a severe and often fatal hemorrhagic fever in humans and other mammals, known as Ebola virus disease. Ebola virus has caused the majority of human deaths from EVD, and is the cause of the 2013–2014 Ebola virus epidemic in West Africa, which has resulted in at least 17,145 suspected cases and 6,405 confirmed deaths. Ebola virus and its genus were both originally named for Zaire, the country where it was first described, and was at first suspected to be a new "strain" of the closely related Marburg virus. The virus was renamed "Ebola virus" in 2010 to avoid confusion. Ebola virus is the single member of the species Zaire ebolavirus, which is the type species for the genus Ebolavirus, family Filoviridae, order Mononegavirales. The natural reservoir of Ebola virus is believed to be bats, particularly fruit bats, and it is primarily transmitted between humans and from animals to humans through body fluids. The EBOV genome is a single-stranded RNA approximately 19,000 nucleotides long.

2-[(7-hydroxy-8-methyl-2-oxochromen-4-yl)methylsulfanyl]-4,6-dimethylpyridine-3-carbonitrile for use in the treatment of ebola virus

The application of 2-[(7-hydroxy-8-methyl-2-oxochrome-4-yl)methylthiosulfase]-4,6-dimethylpyridine-3-carbamate in the treatment of Ebola virus belongs to the field of pharmaceutical technology. This invention addresses the technical problem of the lack of effective anti-Ebola virus drugs in the prior art by providing 2-[(7-hydroxy-8-methyl-2-oxochrome-4-yl)methylthiosulfase]-4,6-dimethylpyridine-3-carbamate, which can effectively inhibit Ebola virus replication within a non-toxic range. The compound exhibits good anti-infective effects against SUDV, BDBV, and TAFV viruses and can be used to prepare safe and effective broad-spectrum anti-Ebola virus drugs.
Owner:CHANGCHUN UNIV OF CHINESE MEDICINE +1

Antiviral compounds

PendingUS20260109724A1Organic active ingredientsGroup 5/15 element organic compoundsEbola virusHcv hepatitis c virus
Owner:GILEAD SCIENCES INC

NEUTRALIZING ANTIBODIES AGAINST EBOLA VIRUS GLYCOPROTEIN AND THEIR USE

Owner:THE GOVERNMENT OF THE UNITED STATES OF AMERICA AS REPRESENTED BY THE SECRETARY DEPARTMENT OF HEALTH & HUMAN SERVICES

Use of 4,4'-(benzo[c][1,2,5]thiadiazole-4,7-diyl)diphenylamine compounds in the preparation of anti-ebola virus drugs

4,4'-(benzo[C][1,2,5]thiadiazole-4,7-diyl)dianiline compound in the preparation of anti-Ebola virus drugs belongs to the technical field of medicines.The present application provides 4,4'-(benzo[C][1,2,5]thiadiazole-4,7-diyl)dianiline compound to solve the technical problem of lack of effective anti-Ebola virus drugs in the prior art, and the molecular formula of the compound is C 18 H 14 N4S.The 4,4'-(benzo[C][1,2,5]thiadiazole-4,7-diyl)dianiline compound provided by the present application can effectively inhibit the replication and infection of Ebola virus in the non-toxic range, and has good anti-infection effect on Sudan virus SUDV, Bundibugyo virus BDBV and Taï Forest virus TAFV, and the compound can be applied to prepare safe and effective broad-spectrum anti-Ebola virus drugs.
Owner:CHANGCHUN UNIV OF CHINESE MEDICINE +1

4' - halogen containing nucleotide and nucleoside therapeutic compositions and uses related thereto

PendingJP2026027247AOrganic active ingredientsSugar derivativesEastern equine encephalitis virusNucleotide
To provide pharmaceutical compositions and methods for the treatment of viral infections.SOLUTION: Halogen-containing nucleotide and nucleoside therapeutic compositions and uses related thereto are disclosed. In certain embodiments, the disclosure relates to the treatment or prevention of viral infections. Such viral infections may include togaviridae, bunyaviridae, arenaviridae, coronaviridae, flaviviridae, picornaviridae, eastern equine encephalitis, western equine encephalitis, and Venezuelan equine encephalitis (EEE, WEE, and VEE, respectively), chikungunya (CHIK), Ebola, flu, RSV, and Zika virus infections.SELECTED DRAWING: Figure 1
Owner:EMORY UNIVERSITY

4'-halogen-containing nucleotide and nucleoside therapeutic compositions and related uses

PendingJP2026062641AOrganic active ingredientsSugar derivativesEastern equine encephalitis virusNucleotide
To provide a novel treatment for viral infections. [Solution] Halogen-containing nucleotide and nucleoside therapeutic compositions and related uses are disclosed. In certain embodiments, the disclosure relates to the treatment or prevention of viral infections. Such viral infections may include Togaviridae, Bunyaviridae, Arenaviridae, Coronaviridae, Flaviviridae, Picornaviridae, Eastern equine encephalitis, Western equine encephalitis, and Venezuelan equine encephalitis (EEE, WEE, and VEE, respectively), Chikungunya fever (CHIK), Ebola, influenza, RSV, and Zika virus infection. In exemplary embodiments, the compound is selected from the following: TIFF2026062641000590.tif42170
Owner:EMORY UNIVERSITY

Human antibodies against Ebola virus glycoproteins

ActiveJP7796918B2FungiBacteriaEbola virusAntiendomysial antibodies
To provide human antibodies to Ebola virus glycoproteins.SOLUTION: The present invention provides monoclonal antibodies, or antigen-binding fragments thereof, that bind to Ebola virus glycoproteins, pharmaceutical compositions comprising the antibodies, and methods of use. The antibodies of the invention are useful for inhibiting or neutralizing Ebola virus activity, thus providing means of treating or preventing Ebola virus infection in humans. In some embodiments, the invention provides for use of one or more antibodies that bind to the Ebola virus for preventing viral attachment and / or entry into host cells. The antibodies of the invention may be used prophylactically or therapeutically and may be used alone or in combination with one or more other anti-viral agents or vaccines.SELECTED DRAWING: None
Owner:REGENERON PHARMACEUTICALS INC